2018 Nov 2;8(1):16281. doi: 10.1038/s41598-018-34524-2. Ackermann M*, Kempf H*, Hetzel M, Hesse C, Hashtchin AR, Brinkert K, Schott JW, Haake K, Kühnel MP, Glage S, Figueiredo C, Jonigk D, Sewald K, Schambach [...] A, Becker J, Baumann K, Bruhn M, Haake K, Hashtchin AR, Gensch I , Korte A, Behrens YL, Zhang SY, Casanova JL, Bär C, Lachmann N , Thum T, Kalinke U. Type I IFNs Decrease SARS-CoV-2 Replication in Human [...] Erazo-Borrás L, Han JE, Pillay B, Ponsin K, Chaldebas M, Philippot Q, Bohlen J, Rosain J, Le Voyer T, Janotte T, Amarajeeva K, Soudée C, Brollo M, Wiegmann K, Marquant Q, Seeleuthner Y, Lee D, Lainé C

authors contributed equally Perner F . , Schnoeder T.M., Xiong Y., Jayavelu A.K., Mashamba N., Tubio Santamaria N., Huber N., Todorova K., Hatton C., Perner B., Eifert T., Murphy C., Hartmann M., Hoell J.I., [...] transcripts to control cell competition in AML . 2022. Leukemia ; 36(2):426-437 Perner F ., Gadrey J.Y., Xiong Y., Hatton C., Eschle B.K., Weiss A., Stauffer F., Gaul C., Tiedt R., Perry J.A., Armstrong S [...] trial of the menin inhibitor revumenib for KMT2A-rearranged or NPM1-mutant leukemia . 2023. Nature . Mar;615(7954):920-924. Tubío-Santamaría N., Jayavelu A.K., Schnoeder T.M., Eifert T., Hsu C.J., Perner

Foinquinos A, José GS, Beaumont J, Bock K, Grote-Levi L, Xiao K, Bär C, Pfanne A, Just A, Zimmer K, Ngoy S, López B, Ravassa S, Samolovac S, Janssen-Peters H, Remke J, Scherf K, Dangwal S, Piccoli MT, Kleemiss [...] doi: 10.3390/cells9112377.PMID: 33143316 Bork T, Liang W, Yamahara K, Lee P, Tian Z, Liu S, Schell C, Thedieck K, Hartleben B , Patel K, Tharaux PL, Lenoir O, Huber TB. Podocytes maintain high basal levels [...] . Dev Biol. 2020 Mar 15;459(2):138-148. doi: 10.1016/j.ydbio.2019.12.007. Epub 2019 Dec 14.PMID: 31846624 Mishra A, Emamgholi F, Erlangga Z, Hartleben B , Unger K, Wolff K, Teichmann U, Kessel M, Woller

Geiser T, Geissler K, Gläser S, Handzhiev S, Jonigk D , Koschel D, Kreuter M, Leuschner G, Markart P, Prasse A, Schönfeld N, Schupp JC, Sitter H, Müller-Quernheim J, Costabel U. S2K Guideline for Diagnosis [...] Jonigk D , Yamazoe T, Yamatsuta K, Mizuno H, Ludwig S, Noé F, Kjolby M, Braun A, Sheltzer JM, Pöhlmann S. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite [...] factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18. J Mol Histol. 2021 Dec;52(6):1257-1264. doi: 10.1007/s10735-021-09980-2. Epub 2021

205(5): 548-57 Brakensiek K, Länger F, Kreipe H, Lehmann U: Absence of p21 (CIP 1), p27 (KIP 1) and p57 (KIP 2) methylation in MDS and AML. Leuk Res 2005; 29(11): 1357-60 Brakensiek K, Länger F, Schlegelberger [...] leukemia treated with imatinib. Cancer Genet Cytogenet 2005; 159(2): 164-7 Germeshausen M, Schulze H, Kratz C, Wilkens L, Repp R, Shannon K, Welte K, Ballmaier M: An acquired G-CSF receptor mutation results in [...] A, Metzig K, Hasemeier B, Kreipe H, Lehmann U: Down-regulation of the IGF-2/H19 locus during normal and malignant hematopoiesis is independent of the imprinting pattern. Int J Oncol 2005; 26(2): 499-507

Epping J, Lange K, Geyer S (2021). Development of comorbidities in type 2 diabetes between 2005 and 2017 using German claims data. Scientific Reports, 11(1). DOI: 10.1038/s41598-021-90611-x. Sperlich S , [...] Kommunikation und Gesprächsführung im Modul "Diagnostische Methoden I" (2. Studienjahr) Psychologische und soziologische Grundlagen der Medizin (2. Studienjahr) Kleingruppen im Rahmen des Propädeutikums (1. St [...] 35, 2. doi:https://doi.org/10.1093/eurpub/ckaf161.870 Safieddine B, Geyer S , Sperlich S, Grasshoff J, Beller J. A vertical-horizontal approach to examine social inequalities in early onset type 2 diabetes

2013; 54(2): 410-24 Junker K, Länger F , Schnabel P: [Update pulmonary pathology : Report of the Pulmonary Pathology Working Group of the German Society of Pathology]. Pathologe 2013; 34 Suppl 2: 304-307 [...] Brockhoff G, Specht K, Hasmann M, Feuerhake F : Detection of Truncated HER2 Forms in Formalin-Fixed, Paraffin-Embedded Breast Cancer Tissue Captures Heterogeneity and Is Not Affected by HER2-Targeted Therapy [...] Büsche G , Hussein K , Kreipe H : SRSF2 mutation is present in the hypercellular and prefibrotic stage of primary myelofibrosis. Blood 2013; 121(19): 4011-4012 [Correspondence] Liu X, Wu G, Shan Y, Hartmann

a J, Smith K, Sommer L, Stock K, Ströbel P, Strobl S, Titze U, Weirich G, Weis J, Werner M, Wickenhauser C, Wiech T, Wild P, Welte T, von Stillfried S, Boor P. Virchows Arch. 2022 Aug;481(2):139-159. doi: [...] Guidance in HR+/HER2- Early Breast Cancer. Nitz UA, Gluz O, Kümmel S, Christgen M, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, Darsow M, Krauss K, Nuding B, Thill M [...] weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial. Nitz U, Gluz O, Graeser

Lange K, Geyer S (2021). Development of comorbidities in type 2 diabetes between 2005 and 2017 using German claims data. Scientific Reports. 2021;11(1). https://doi.org/10.1038/s41598-021-90611-x. Klar [...] Public Health. 25(2):215-22. DOI 10.1007/s10389-016-0771-2 Geyer S (2016). Die quantitative Analyse von Gesundheit und Krankheit. In: Soziologie von Gesundheit und Krankheit, M. Richter & K. Hurrelmann, (Hrsg [...] Lange K, Geyer S (2021). Development of comorbidities in type 2 diabetes between 2005 and 2017 using German claims data. Scientific Reports. 2021;11(1). https://doi.org/10.1038/s41598-021-90611-x . Sperlich

SARS-COV-2 negative-sense RNA and promotes nascent viral RNA synthesis -> Cell 186(22):4834-4850.e23. DOI: 10.1016/j.cell.2023.09.002 Djakovic L, Hennig T, Reinisch K, Milić A, Whisnant AW, Wolf K, Weiß E [...] Kirschenbaum D, Abadie K, Miska EA, Friedel CC, Amit I, Micura R, Dölken L . (2022). Time-resolved single-cell RNA-seq using metabolic RNA labelling. -> Nature Reviews Methods Primers 2, 77. https://www.nature [...] Herpesviral manipulation of the host transcriptional machinery Unlike other viruses such as SARS-CoV-2, herpesviruses uniquely exploit the host’s transcriptional machinery to express their large DNA genomes